SORT BY

FILTER BY

also on other fortune lists

company facts

f500 stats

Fortune 500

Gabby Jones — Bloomberg via Getty Images

37

Johnson & Johnson

JNJ

The 132-year-old company, which specializes in pharmaceuticals, consumer health care, and medical devices, sells a wide array of health and beauty products including the Johnson’s Baby line, Neutrogena, Listerine, Band Aids, Tylenol, and Motrin. The company has been at the center of lawsuits concerning products that contain talc and their possible link to ovarian cancer and lung-related cancers, and has also been sued in connection with the opioid epidemic. But even amid legal conflicts and competition and pricing pressures in the industry, the company saw domestic sales increase 5.4% and international sales increase 7.4% in 2017. The company raised its sales outlook for 2018 due to the high performance of its pharmaceutical business, particularly cancer drugs.

Looking for leads, investment insights, or competitive intelligence?

CEO

Alex Gorsky

CEO Title

Chairman & Chief Executive Officer

Sector

Health Care

Industry

Pharmaceuticals

HQ Location

New Brunswick, N.J.

Years on Fortune 500 List

24

Employees

134,000

Key Financials (Last Fiscal Year)
$ millions% change
Revenues ($M)$76,4506.3%
Profits ($M)$1,300.0-92.1%
Assets ($M)$157,303
Total Stockholder Equity ($M)$60,160
Market Value — as of March 29, 2018 ($M)$343,780
Profit Ratios
Profit as % of Revenues1.7%
Profits as % of Assets0.8%
Profits as % of Stockholder Equity2.2%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)0.47
EPS % Change (from 2016)-92.1%
EPS % Change (5 year annual rate)-34.4%
EPS % Change (10 year annual rate)-18.5%
Total Return
Total Return to Investors (2017)24.3%
Total Return to Investors (5 year, annualized)18.0%
Total Return to Investors (10 year, annualized)11.0%
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Johnson & Johnson

6 More States Just Sued the Oxycontin Maker. How It Could Dramatically Alter the Price of an Opioid Settlement

The decision to sue is seen as an acknowledgment opioid makers won’t get serious about settling until the cases go to trial.

Read More →
Do We Need to Rethink the Meaning of Design Thinking?

Top designers weigh in on one of design's most deeply held concepts.

Read More →